[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"migraine-in-adults\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:migraine-in-adults":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,75,109,134,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100619758","yogabased-movements-for-primary-headaches-migraine-andor-cluster-headache---yourhead-100619758",false,"NCT07348783","Yogabased Movements for Primary Headaches (Migraine and\u002For Cluster Headache) - YOURHEAD","Yogabased Movements Weekly (Online Live or Face to Face) for Primary Headaches","Inclusion Criteria:\n\n* Diagnosed chronic migraine and\u002For cluster (Hortons) headache\n* Men and women 18-65 years\n* Diagnosed with chronic\u002Fhigh frequency migraine (≥15 headache days\u002Fmonth with at least ≥8 with migraine)\n* Diagnosed with chronic cluster head ache (i.e shorter remission than 3 months per year), diagnosed according to ICHD-III criteria.\n* Ability to perform yoga based moments and to give consent.\n* Internet connection with computer\u002Fipad\u002Fmobile to perform digitally\u002Ftele-health instructions\n* Willing to use wristwatch for actigraphy\n* Willing to leave blood samples in laboratory\n\nExclusion Criteria:\n\n* Recent or planned operations during the last 6 weeks\n* Drug dependence, alcohol dependence, mental disorders as psychosis, bipolar disorder, anxiety as PTSD etc)\n* Parallel enrollment in other clinical trails\n* Unmedicated high blood pressure, heart disease as heart failure\n* Non Swedish speaking\n* Not able to perform low intensity exercise at home or FTF (face to face) - both online or live.\n* Participants unsure to participate due to drug addiction or other causes\n* Disorientation and not able to inform regarding other serious conditions","ALL","18 Years","65 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Brief Summary:\n\nMigraine and\u002For Cluster Headache: Study Overview\n\n\\*\\*Background:\\*\\* Migraine and cluster headache are two primary headache disorders that significantly impact quality of life and functionality in those affected. According to the WHO's recurring burden of disease reports, migraine is among the neurological conditions responsible for the highest number of years lost due to illness. The headaches associated with migraine and cluster headache range from moderate to severe and cause great suffering. Available treatments do not work for everyone and are often associated with adverse side effects. Physical activity has been shown in several studies to have a positive effect on headache. Given the high prevalence of mental health issues, stress, and sleep problems within this patient group, relaxation and low-intensity exercise such as yoga-based movements (YB) could potentially help individuals improve sleep and well-being, while also providing some preventive effect on headaches.\n\n\\*\\*Hypothesis:\\*\\*\n\nIndividuals with severe migraine or cluster headache have a strong need for new treatment options. Alternative therapies such as yoga-based exercises, when combined with standard medical treatment as per clinical guidelines, may positively impact:\n\nHeadache symptoms, Sleep quality and Overall life quality\n\n* Purpose and Goals:\\*\\* This randomized controlled study aims to evaluate the effect of a web-based yoga (YB) or live face to face (FTF) intervention in individuals suffering of primary headaches-mainly chronic migraine and\u002For cluster headache. The study will assess the effect of YB on health-related changes in headache frequency, intensity, and duration associated with primary headache conditions, with a focus headache frequency. A secondary objective is to analyze quality of life, sleep quality, mental health as depression and anxiety. The RCT will also measure objective sleep and biomarkers. We are now summarizing the effects after a pilot study.\n* Relevance for the Patient Group:\\*\\* The core objective of the project is to determine whether yoga-based exercises can serve as a complementary treatment to enhance quality of life and health in patients with severe primary headache. To ensure equal healthcare access, this intervention will be delivered in digital format and\u002For FTF to optimize availability and expand care for individuals with primary headache disorders. These efforts aim to improve life quality and well-being in a vulnerable patient population. Headache conditions often affect individuals in their most productive years, and many live with symptoms for decades. Both work and private life are frequently disrupted, resulting in sick leave and social isolation. Close relatives are also affected, as those suffering from headaches require more recovery time to cope with daily life. With this proposed project, we aim to use physical yoga, rooted in holistic traditional medicine, to help individuals with severe primary headache achieve better physical and mental health-particularly improved sleep quality, which in turn enhances overall life quality.",[27,28,29,30,31,32],"Cluster Headache - Episodic and Chronic","Migraine Headache","Migraine Headache, With or Without Aura","Migraine in Adults","Cluster Headaches and Other Trigeminal Autonomic Cephalgias","Migraine Disorder","RECRUITING","2026-06-23",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":37},"2026-05-01",{"date":41,"type":21},"2027-12-30",{"name":43,"class":44},"Karolinska Institutet","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100643927","phase-1-a-prospective-open-label-study-evaluating-the-effectiveness-of-gepants-for-acute-treatment-of-migraine-in-the-emergency-department-100643927","NCT07667621","A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department","A Prospective, Open-Label Study Evaluating the Effectiveness of Rimegepant ODT or Zavegepant Nasal Spray for Acute Treatment of Migraine in the Emergency Department","Inclusion Criteria:\n\n* • At least 18 years of age\n\n  * Capacity to provide informed consent (without a Representative)\n  * Emergency Department presentation for a headache consistent with migraine, based either on the treating clinical team's judgement, or fulfillment of International Classification of Headache Disorders (ICHD-3) criteria for migraine without aura or with typical aura, or for probable migraine without aura or with typical aura. It is acceptable if current headache duration is \\>72 hours. Must have been headache free for \\>48 hours prior to current attack.\n  * Willing to participate in post-discharge telephone assessments\n  * English and\u002For Spanish speaking patients\n\nExclusion Criteria:\n\n* • Use of intranasal decongestants within 1 hour prior to study drug administration, due to the potential to decrease absorption of intranasal zavegepant.\n\n  * Use of analgesics or abortive headache medications within 60 minutes of study medication administration\n  * Use of the following drug\u002Ffood categories with potential for drug interactions within 7 days or 5 half-lives, whichever is longer: 1) CYP3A strong or moderate inducers, 2) CYP3A4 strong inhibitors, 3) P-glycoprotein (P-gp) inhibitors, 4) OATP1B3 transporter potent inhibitors\u002Finducers, 5) NTCP transporter potent inhibitors\u002Finducers\n  * History of ischemic cardiovascular disease, diabetes, or hypertension (diagnosed or likely based on multiple readings), that was recently diagnosed within 3 months of screening or is currently uncontrolled or unstable\n  * History of any stroke within 3 months, or any lifetime stroke and age ≥65 years\n  * History of significant peripheral vascular disease, as assessed by the investigator or qualified delegate\n  * History of Raynaud's Phenomenon (medically diagnosed, or non-medically diagnosed with affirmative responses to both unusual sensitivity and finger color change with cold exposure)\n  * History of severe hepatic impairment, as assessed by the investigator or qualified delegate\n  * History of kidney disease stage 4 (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2)\n  * History of hypersensitivity reaction to rimegepant, zavegepant, or to any included inactive ingredients\n  * Lifetime use of CGRP-targeting acute or preventive migraine medications\n  * In custody of law enforcement\n  * Current pregnancy or lactation\n\n    * All individuals of childbearing potential must have a negative pregnancy test at screening (urine or serum).\n    * A person is considered to be of childbearing potential if possessing female reproductive organs at birth, post-menarchal, has not reached a post-menopausal state (≥12 continuous months of amenorrhea with no cause identified other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis).",true,{"count":55,"type":21},100,[57],"PHASE1","Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocated to either the rimegepant trial or the zavegepant trial. The study design does not include a placebo or active comparator control group, and the two gepant study drugs are not designed to function as active comparator groups. The objective in this investigation is to examine relief from either rimegepant or zavegepant in separate parallel trials.",[60,61,30,28,62,63,64],"Migraine","Migraine Disease","Acute Migraine","Migraine Without Aura","Migraine With Aura","NOT_YET_RECRUITING","2026-06-20",{"date":68,"type":37},"2026-06-25",{"date":70,"type":21},"2026-07",{"date":72,"type":21},"2027-08",{"name":74,"class":44},"University of South Florida",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":45},"100643788","evaluation-of-the-migraceutics-phase-specific-dietary-supplement-regimen-on-quality-of-life-work-productivity-and-biomarkers-in-adult-migraineurs-the-migraceutics-start-study-100643788","NCT07634146","Evaluation of the Migraceutics® Phase-Specific Dietary Supplement Regimen on Quality of Life, Work Productivity, and Biomarkers in Adult Migraineurs: The Migraceutics® START Study","A Randomized, Sham Supplement- and Care-as-Usual-Controlled Study to Evaluate Migraceutics® Phase-Specific Dietary Supplement Regimen on Quality of Life, Work Productivity, and Biomarkers in Adult Migraineurs: The Migraceutics® START Study","Inclusion Criteria:\n\n* Self-reported history of migraine, based on the International Headache Society (IHS) International Classification of Headache Disorders, 3rd edition (ICHD-3) diagnostic criteria for migraine.\n* Being able to take oral supplements.\n* Agreeing to maintain their regular lifestyle.\n* Access to internet and telephone.\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Presence of any active medical condition or diagnosis other than episodic migraine, including liver or kidney disease or condition.\n* Use of overlapping supplements or interacting medications.\n* Known allergies to study ingredients.\n* Daily use of alcohol, tobacco, or recreational drugs.\n* Participation in any other clinical or interventional study within 30 days prior to baseline or concurrently.",{"count":83,"type":21},920,[24],"The purpose of this study is to evaluate the impact of the Migraceutics® phase-specific dietary supplement regimen on quality of life, work productivity, and biomarkers in adult migraineurs.",[60,61,32,28,87,30,88,89],"Migraine Disability","Menstrual Migraine","Menstrual Migraine (MM) Headaches",[91,92,93,94,95,96,97,98,99],"quality of life","productivity","disability","CGRP","headache","migraine","nutraceuticals","dietary supplement","migraceuticals","2026-06-03",{"date":102,"type":37},"2026-06-08",{"date":104,"type":21},"2026-07-08",{"date":106,"type":21},"2028-06-30",{"name":108,"class":44},"Miracle Wellness LLC",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":45},"100640266","the-effect-of-static-magnetic-fields-on-neuroinflammation-in-migraine-100640266","NCT07584382","The Effect of Static Magnetic Fields on Neuroinflammation in Migraine","Inclusion Criteria:\n\n1. Between 18 and 65 years of age.\n2. Migraine diagnosis must come from a neurologist or other qualified MD, and the diagnosis must meet International Classification of Headache Diagnosis, Version 3 (ICHD-3) beta criteria for migraine according to either of the categories:\n\n   ICHD-3 beta 1.1: Migraine without aura ICHD-3 beta 1.2: Migraine with aura\n3. The frequency of migraine attacks must be at least 4 migraine-days per month.\n4. The duration of the disease must be of at least one year.\n5. Willingness to adhere to daily intervention sessions and complete study procedures.\n6. Able to give written consent in English.\n\nExclusion Criteria:\n\n1. Greater than 20 headache days per month.\n2. Major systemic illness (e.g., brain tumor, severe hypertension) or unstable medical and\u002For psychiatric condition (e.g., suicide risk, requiring immediate treatment) that could compromise protocol adherence.\n3. Evidence of relevant co-morbidity, systemic or not, with potential to substantially interfere with the phenotype of the conditions studied in the present protocol (e.g., history of Type I or Type II diabetes mellitus unless well managed).\n4. A history of neurological disease or injury, including a history of seizures or significant head trauma (i.e., extended loss of consciousness, neurological sequelae, or known structural brain lesion), which may confound the results of the study.\n5. Symptoms that could impact protocol adherence or be disruptive to study participation (e.g., Tourette's, schizophrenia with current psychosis, bipolar 1 disorder, severe OCD, current severe episode of major depression, dissociative disorder, severe PTSD, severe personality disorder, traumatic brain injury, severe agoraphobia).\n6. Medication overuse, using ICHD-3 beta criteria framework for medication overuse.\n7. Other chronic pain disorder whose intensity exceeds the intensity of pain during migraine headaches.\n8. Moderate or high levels of opioid use (\\>60mg Morphine equivalents).\n9. Participation in other concurrent therapeutic trials.\n10. New pharmacotherapy started within 4 weeks of the screening visit or inconsistent pharmacotherapy for the duration of the study that could impact study.\n11. Subjects who are prescribed preventative CGRP medications that include CGRP antibodies and oral CGRP receptor antagonists and have been taking them for \\\u003C3 months before screening.\n12. Meets criteria for active, non-remitted, DSM-V Moderate or Severe Substance Use Disorder, or demonstrates regular substance use (assessed by self-report and\u002For urine screening) in a manner which would impact the protocol.\n13. General magnet helmet, MRI, and PET-CT safety exclusion criteria (e.g., implanted pacemakers or defibrillators, deep brain stimulators, cochlear implants, programmable shunts, ferromagnetic cranial implants, routine use of benzodiazepines or any use in the 2 weeks prior to the scan(s), except clonazepam, lorazepam, and alprazolam, which show very low binding affinity to TSPO, low-affinity binder phenotype from genotyping the TSPO rs6971 polymorphism, pregnancy or breastfeeding, electrical or ferromagnetic implants, claustrophobia, \\>300 lbs, use of certain antibiotics such as minocycline, inability to lie comfortably on a bed inside the scanner for at least 90 minutes)\n14. Any impairment, activity or situation that in the judgment of the Study Coordinator or Principal Investigator would prevent satisfactory completion of the study protocol. This includes unreliable or inconsistent completion of daily check-ins during the intervention period.\n15. Diagnosis of significant cardiovascular or cerebrovascular disease (e.g., congestive heart failure, stroke, cardiac conduction disorders (e.g., bundle branch block, heart block, long Q-T syndrome), history of asystole or non-sustained ventricular tachycardia).\n16. Hypotension (defined as blood pressure \\\u003C90\u002F60mmHG) that would impact study participation.\n17. History of COVID-19 infection within the past 3 months WITH neurological symptoms.\n18. Contraindications to the placement of an arterial line (e.g., abnormal result on the modified Allen's test on both hands, severe Raynaud's syndrome or peripheral neuropathy, bleeding disorder, use of anticoagulants such as Coumadin, Plavix or Lovenox)",{"count":116,"type":21},10,[24],"We are conducting this research in individuals with migraines to find out if a daily magnet helmet application could alter migraine-related brain inflammation. Outcomes will be assessed through examining any changes in Translocator Protein (TSPO) binding on Positron Emission Tomography-Computed Tomography (PET-CT) imaging both before and after the magnet helmet intervention period. Additionally, patient-reported migraine symptoms will be measured using validated questionnaires administered during the four-week pre- and post- intervention monitoring periods.",[30],[121,122,123,124],"Brain imaging","Non-drug self-administered at-home intervention","PET\u002FCT","MRI","2026-05-07",{"date":127,"type":37},"2026-05-13",{"date":129,"type":21},"2026-07-01",{"date":131,"type":21},"2027-09-01",{"name":133,"class":44},"Marco Loggia",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":45},"100637038","sleep-stress-and-migraine---an-observational-and-training-study-100637038","NCT07573488","Sleep, Stress and Migraine - an Observational and Training Study","Migraine Sleep Study (MiSleepS) - The Role of Sleep and Stress as a Trigger in Migraine","MiSleepS","Inclusion Criteria:\n\n* Adults aged between 18 and 65 years\n* Diagnosis of episodic migraine according to The International Classification of Headache Disorders (ICHD-3) criteria confirmed by our headache specialists\n* 4 to 14 headache days per month (mean value based on the 3 months prior to study enrollment)\n* Ability to give informed consent and to adhere to the study protocol\n* Sufficient German language comprehension to follow the study procedures and answer all questions related to the study outcomes\n* Stable migraine medication regimen for the past 3 months and throughout the study period\n\nExclusion Criteria:\n\n* Diagnosis of sleep disorders that could interfere with the sleep intervention, such as obstructive sleep apnea with an apnea-hypopnea index (AHI) \\> 15, Restless Legs Syndrome, frequent (i.e. weekly) Non-rapid eye movement (NREM) sleep parasomnia, REM Behavior Disorder (RBD)\n* Current diagnosis of a psychiatric disorder that is inadequately treated or therapy-resistant and may interfere with study participation or adherence to study procedures (this includes, but is not limited to: schizophrenia, schizoaffective disorder, bipolar disorder (type I), post-traumatic stress disorder with active symptoms, or major depressive disorder with ongoing functional impairment despite treatment). Diagnosis must be confirmed by clinical history or treating physician.\n* Regular use of benzodiazepines and other central nervous system (CNS)-depressant substances (self-reported)\n* Concomitant steroid medication (self-reported)\n* Known or suspected alcohol, drug or medication abuse (i.e. \\> 0.5 l wine or 1 l beer per day)\n* Inability to follow the procedures of the study (e.g., due to language problems, cognitive deficits, instable home situation)\n* Concurrent participation in another study involving drug and behavioral interventions within 3 months prior to and during the present study, as well as participation in an ongoing study with data collection through SEMA3\n* Planned medical intervention of substantial relevance requiring hospitalization for more than 24 hours (e.g. surgery) during intervention (routine assessments, e.g. check-ups will be allowed)\n* Shift work with working during the night\n* Travelling more than 2 time zones in the last month before the observation or intervention periods or during the study\n* Persons who are pregnant or breastfeeding",{"count":20,"type":21},[24],"The MiSleepS study investigates how sleep disturbances and stress are linked to migraine attacks. Participants wear a device called a WHOOP band, which tracks sleep and body signals, and answer brief daily questions via a smartphone app about their sleep, stress levels, and migraine symptoms. The goal is to identify personal patterns that may contribute to migraine. Based on these insights, participants receive individualized recommendations to improve their sleep and daily routines - aiming to reduce migraine attacks in the long term without medication. The study is conducted at the University Hospital Zurich and is aimed at adults with episodic migraine.",[60,146,147,30],"Sleep Disorder (Disorder)","Stress",[96,149,150,151,152,153],"behavioral therapy","sleep hygiene","stress management","migraine triggers","non-medical prophylaxis","2026-05-03",{"date":125,"type":37},{"date":157,"type":21},"2026-05-18",{"date":159,"type":21},"2027-07-31",{"name":161,"class":44},"Susanne Wegener",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":45},"100594128","neuro-complex--multi-supplements-for-migraine-prevention-100594128","NCT07015411","Neuro-Complex & Multi Supplements for Migraine Prevention","Effectiveness of an Orally Administered and Combined Neuro-Complex & Multi Supplements in the Prevention of Migraine in Adult","NeuroCare","Inclusion Criteria:\n\n* Male or female between 18 and 75 years;\n* Diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura)\n\n  * At least 5 attacks fulfilling the criteria below\n  * Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)\n  * Headache has at least two of the following characteristics\n\n    * unilateral location\n    * pulsating quality\n    * moderate or severe pain intensity\n    * aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)\n  * During headache at least one of the following:\n\n    * nausea and\u002For vomiting\n    * photophobia and phonophobia\n  * Not attributed to another disorder\n* Migraine frequency of at least 6 headache days per month during the last 3 months;\n* Stable body mass index (BMI) between 18.5-35.0;\n* Stable medication use with no significant changes in prophylactic or acute migraine treatments in the past 3 months, and willingness to maintain or reduce (if not needed) this throughout the study period;\n* Willingness and ability to complete an ediary (mobile app or web based) and to follow the instruction of the study;\n* Having signed an informed consent.\n\nExclusion Criteria:\n\n* Other primary head pain disorders such as but not restricted to tension-type headache, cluster headache, fibromyalgia;\n* Secondary head pain due to trauma, injury, infections;\n* Medication overuse for headache defined as acute headache medication \\>10-15 days per month depending on the half-life of the medication (left to PI discretion);\n* Severe medical conditions affecting absorption and metabolism of the product, including but not restricted to chronic use of laxatives;\n* Bariatric surgery;\n* Severe psychiatric conditions that could interfere with diary compliance or assessment of the product (e.g., severe depression or cognitive impairments) left to investigator discretion;\n* Use of other dietary supplements that could potentially affect migraines, unless willing to discontinue them before the study begins (wash out period of 3 months);\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;\n* Women of childbearing potential without medically effective form of contraception unless they can confirm they've had bilateral tubal ligation or that their male partner has had a vasectomy;\n* Specific allergies or intolerance to components of the product;\n* Recent migraine interventions: Such as Botox injections (except if considered as a stable treatment, i.e. not the first injection), nerve blocks, or other invasive treatments in the last 6 months;\n* Concurrent participation in another clinical study or having participated in the last 3 months:\n* Swallowing disorders;\n* Chronic drug and alcohol abuse;\n* Anticoagulants (coumarin compound);\n* Hepatic or biliar truct disorders;\n* Active malignancy and immunosuppression therapy;\n* Hypothyroidism;\n* Close collaborators of investigational team, of sponsor or of study coordinator;\n* Under guardianship or judiciable protection.","75 Years",{"count":172,"type":21},120,[24],"The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \\& Multi after 8 weeks of product intake on participants with diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura).\n\nThe main endpoint of this clinical trial is :\n\nThe mean changes in migraine days per month (MDM) after 8 weeks of supplementation.\n\nParticipants will:\n\nOrally consume two caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).",[28,60,30],[60,177,178,179,95,180],"Neuro-Complex","Multi","Supplement","nutrients","2025-06-03",{"date":183,"type":37},"2025-06-11",{"date":185,"type":37},"2025-05-15",{"date":187,"type":21},"2025-12-16",{"name":189,"class":190},"Benfida, a department of Handi-Move","INDUSTRY"]